[Registry] Trial Evaluating the RadTox Assay for Predicting GI Toxicity Associated with Radiation Therapy
Condition: Prostate Cancer
Sponsor: DiaCarta, Inc.
Protocol DIA.0009. Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly from Plasma.
Registry trial involving blood work drawn at specific timepoints during the radiation therapy of prostate cancer patients without metastatic disease. The trial will evaluate the ability of the DiaCarta's RadTox assay to predict the likelihood of gastrointestinal toxicity associated with radiation therapy directed at the prostate.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.